Business Wire

NC-LENOVO

10.11.2021 15:02:09 CET | Business Wire | Press release

Share
Lenovo Becomes the Preferred Workstation Innovation Partner for DreamWorks Animation

Lenovo™ today announced that DreamWorks Animation has selected Lenovo as its preferred workstation innovation partner to deliver the high-end power and performance needed to bring its next cutting-edge animation feature films to life. This PC collaboration further strengthens the companies’ partnership, as it expands upon the technology leader’s current role as DreamWorks’ data center innovation partner. As part of this multi-year agreement, DreamWorks will deploy Lenovo workstations, including the ThinkStation P620 and ThinkStation P920 , across all departments for the development of content and characters, including the highly anticipated release of the studio’s upcoming film, “The Bad Guys.”

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211110005429/en/

The extension of this partnership follows the rollout of a new on-premises Lenovo computing infrastructure designed to transform DreamWorks’ data center into a high-performance, ultra-scalable and sustainable operations center for all of its content creation.

With consumer demand for premium animated content at an all-time high, DreamWorks Animation looked to Lenovo’s Intelligent Devices Group to find innovative workstation solutions that could keep up with its ever-scaling ambitions, increasingly complex workflows and faster production timelines. Designed for high productivity, Lenovo workstations are engineered for power, performance and industry-leading reliability that allow artists to bring their creative ideas to life.

“At DreamWorks, the ability to operate our workflows at the speed of our creative thought process is critical in capturing those instant moments of expression that shape the unforgettable experiences our animators and creative professionals develop. Workstations need to exceed the demands of our artists’ relentless imaginations. Hardware needs to be an enabler; harnessing performance and speed to meet their expectations,” said Bill Ballew, Chief Technology Officer at DreamWorks. “We had the opportunity to test Lenovo’s ThinkStation P620 workstation and realized it’s a game changer for our workflows. Built on the AMD Ryzen™ Threadripper™ PRO architecture, the ThinkStation P620 drives new and improved performance for multi-threaded application environments that our team can take full advantage of.”

From 3D modeling, rigging, surfacing, and simulations to high performance animation and creating hyper-photorealistic renderings, DreamWorks Animation specialists, artists and engineers alike leverage high performance compute capabilities. By relying on the flexibility and future-proofed platforms that Lenovo’s workstations deliver, the DreamWorks’ team can focus on their creative ambitions knowing they are equipped with the world-class technology necessary to meet those complex workflows - now and in the years ahead. In addition to the Lenovo ThinkStation P620, DreamWorks Animation will also be able to take advantage of Lenovo’s most advanced dual processor workstation, the ThinkStation P920. Built with the latest generation of Intel® Xeon® processors, the workstation’s extreme performance will help DreamWorks accelerate their most challenging workflows in a production studio environment.

“We’re excited to expand our partnership with DreamWorks Animation and equip them with workstations that help accelerate their increasingly demanding workflows,” said Rob Herman, Vice President of Lenovo’s Workstation and Client AI Business Unit. “Our workstation collaboration further exemplifies Lenovo’s ability to holistically support our customers with the most advanced technology solutions available, allowing them to innovate faster and transform their respective industries.”

To learn more about how DreamWorks Animation is strengthening its partnership with Lenovo to bring about the next evolution of production, visit: https://techtoday.lenovo.com/us/en/workstations

About Lenovo

Lenovo (HKSE: 992) (ADR: LNVGY) is a US$60 billion revenue Fortune Global 500 company serving customers in 180 markets around the world. Focused on a bold vision to deliver smarter technology for all, we are developing world-changing technologies that power (through devices and infrastructure) and empower (through solutions, services and software) millions of customers every day and together create a more inclusive, trustworthy and sustainable digital society for everyone, everywhere. To find out more visit https://www.lenovo.com and read about the latest news via our StoryHub .

LENOVO, THINKSTATION and THINKPAD are trademarks of Lenovo. AMD and RYZEN™ are trademarks of Advanced Micro Devices, Inc. Intel, Intel Core and vPro are trademarks of Intel Corporation or its subsidiaries in the U.S. and/or other countries. ©2021, Lenovo Group Limited.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye